Cargando…

Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders

Patients with lymphoproliferative disorders such as chronic lymphocytic leukemia and mantle cell lymphoma (MCL) who are resistant to covalent Bruton tyrosine kinase inhibitors (cBTKis), especially if also venetoclax refractory, have an unmet therapeutic need. Pirtobrutinib, a noncovalent BTKi, achie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Philip A., Tam, Constantine S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2023
Materias:	Blood Spotlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646821/ https://www.ncbi.nlm.nih.gov/pubmed/37156004 http://dx.doi.org/10.1182/blood.2023020240

Ejemplares similares

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
por: Blombery, Piers, et al.
Publicado: (2022)

Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor
por: Gomez, Eliana B., et al.
Publicado: (2023)

Anticoagulation in hospitalized patients with COVID-19
por: Baumann Kreuziger, Lisa, et al.
Publicado: (2022)

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients
por: Treon, Steven P., et al.
Publicado: (2020)

Vaccine-induced immune thrombotic thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2023)

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma
por: Carbone, Antonino, et al.
Publicado: (2023)

How should we use convalescent plasma therapies for the management of COVID-19?
por: Wood, Erica M., et al.
Publicado: (2021)

VEXAS syndrome
por: Grayson, Peter C., et al.
Publicado: (2021)

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know
por: Arepally, Gowthami M., et al.
Publicado: (2021)

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Minimal information for reporting a genomics experiment
por: Dreval, Kostiantyn, et al.
Publicado: (2022)

Hemolysis, free hemoglobin toxicity, and scavenger protein therapeutics
por: Vallelian, Florence, et al.
Publicado: (2022)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

FGF21 regulates alcohol intake: New hopes on the rise for alcohol use disorder treatment?
por: Wang, Tammy, et al.
Publicado: (2022)

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
por: Scarfò, Lydia, et al.
Publicado: (2023)

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

S146: GENOMIC EVOLUTION AND RESISTANCE TO PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR (CBTKI) PRE-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS: RESULTS FROM THE PHASE I/II BRUIN STUDY
por: Brown, Jennifer R., et al.
Publicado: (2023)

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
por: Eyre, T. A., et al.
Publicado: (2022)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

P1088: COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS
por: Lamanna, Nicole, et al.
Publicado: (2023)

Management of refractory intramural left ventricular summit ventricular arrhythmia: Acute success using bipolar radiofrequency catheter ablation with recurrence
por: Sudo, Koji, et al.
Publicado: (2023)

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY
por: Eyre, T. A., et al.
Publicado: (2022)

Heightening the awareness of headache disorders
Publicado: (2004)

The potential of pirtobrutinib in multiple B-cell malignancies
por: Jensen, Jeffrey L., et al.
Publicado: (2022)

Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors
por: Burkart, Madelyn, et al.
Publicado: (2022)

Technical challenges of studying early human development
por: Rugg-Gunn, Peter J., et al.
Publicado: (2023)

New Potential for Plug-in Hybrids
por: Goppelt, Gernot
Publicado: (2021)

New Potential for Plug-in Hybrids
por: Goppelt, Gernot
Publicado: (2021)

With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors
por: Mainardi, Sara
Publicado: (2023)

CTLA-4 and Autoimmunity: New Twists in the Tale
por: Walker, Lucy S.K.
Publicado: (2015)

Straightening up is required to nucleate new microtubules
por: Gardner, Melissa K.
Publicado: (2021)

Cell death leaves a new TRAIL
por: Overholtzer, Michael
Publicado: (2021)

A new day for human challenge trials?
por: Rohrig, Abie, et al.
Publicado: (2022)

A Paradigm Shift in China - The New Powertrain Mix
por: Backhaus, Richard
Publicado: (2020)

A Paradigm Shift in China - The New Powertrain Mix
por: Backhaus, Richard
Publicado: (2020)

Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China
por: Yan, Yuting, et al.
Publicado: (2023)

New migraine prophylaxis compounds from serendipity: gambling or wisdom?
Publicado: (2004)

Shooting through time: new insights from transcriptomic data
por: Harrison, C. Jill
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_prmt4s6sufipd5c3o6ijl8do4p